Prognostic impact of CD10 expression in clinical outcome of invasive breast carcinoma
详细信息 查看全文
- 作者：Thi-Ngoc Diem Vo ; Eiji Mekata ; Tomoko Umeda ; Hajime Abe ; Yuki Kawai…
- 关键词：CD10± (negative or very weakly positive staining) ; CD10+ (weakly positive staining) ; CD10++ (strongly positive staining) ; Invasive breast carcinoma (IBC) ; Lymph ; node (LN)
- 刊名：Breast Cancer
- 出版年：2015
- 出版时间：March 2015
- 年：2015
- 卷：22
- 期：2
- 页码：117-128
- 全文大小：2,886 KB
- 参考文献：1. Saika K, Sobue T. Epidemiology of breast cancer in Japan and the US. JAMA. 2009;52(1):39-4.
2. Elston WC, Ellis OI, Pinder ES. Pathological prognostic factors in breast cancer. Crit Rev Oncol Hematol. 1999;31:209-3. CrossRef
3. Mueller MM, Fusenig NE. Friends or foes—bipolar effects of the tumor stroma in cancer. Nat Rev Cancer. 2004;4:839-9. CrossRef
4. Edwards MJ, Bonadonna G, Valagussa P, Gamel JW. End points in the analysis of breast cancer survival: relapse versus death from tumor. Surgery. 1998;124:197-02. CrossRef
5. Maguer-Satta V, Besan?on R, Bachelard-Cascales E. Concise review: neutral endopeptidase (CD10): a multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells. 2011;29:389-6. CrossRef
6. Letarte M, Vera S, Tran R, Addis JB, Onizuka RJ, Quackenbush EJ, et al. Common acute lymphocytic leukemia antigen is identical to neutral endopeptidase. J Exp Med. 1988;168:1247-3. CrossRef
7. Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D’Adamio L, Hersh LB, et al. Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 (‘enkephalinase-: direct evidence by cDNA transfection analysis. Proc Natl Acad Sci. 1989;86:297-01.
8. Koehn JA, Norman JA, Jones BN, LeSoeur L, Sakane Y, Ghai RD. Degradation of atrial natriuretic factor by kidney cortex membranes. J Biol Chem. 1987;262:11623-.
9. Stephenson SL, Kenny AJ. The hydrolysis of human atrial natriuretic peptide by pig kidney microvillar membranes is initiated by endopeptidase-24.11. Biochem J. 1987;243:183-.
10. Yasuda M, Itoh J, Satoh Y, Kumaki N, Tsukinoki K, Ogane N, Osamura RY. Availability of CD10 as a histopathological diagnostic marker. Acta Histochem Cytochem. 2005;38(1):17-4. CrossRef
11. Terauchi M, Kajiyama H, Shibata K, Ino K, Mizutani S, Kikkawa F. Anti-progressive effect of neutral endopeptidase 24.11 (NEP/CD10) on cervical carcinoma in vitro and in vivo. Oncology. 2005;69:52-2. CrossRef
12. Tokuhara T, Adachi M, Hashida H, Ishida H, Taki T, Higashiyama M, et al. Neutral endopeptidase/CD10 and aminopeptidase N/CD13 gene expression as a prognostic factor in non-small cell lung cancer. Jpn J Thorac Cardiovasc Surg. 2001;49:489-6. CrossRef
13. Huang WB, Zhou XJ, Chen JY, Zhang LH, Meng K, Ma HH, et al. CD10-positive stromal cells in gastric carcinoma: correlation with invasion and metastasis. Jpn J Clin Oncol. 2005;35:245-0. CrossRef
14. Deschamps L, Handra-Luca A, O’Toole D, Sauvanet A, Ruszniewski P, Belghiti J, et al. CD10 expression in pancreatic endocrine tumors: correlation with prognostic factors and survival. Hum Pathol. 2006;37:802-. CrossRef
15. Khanh Do T, Mekata E, Mukaisho K. Prognostic role of CD10+ myeloid cells in association with tumor budding at the invasion front of colorectal cancer. Cancer Sci. 2011;102(9):1724-3.
16. Fujita S, Taniguchi H, Yao T, Shimoda T, Ueno H, Hirai T, et al. Multi-institutional study of risk factors of liver metastasis from colorectal cancer: correlation with CD10 expression. Int J Colorectal Dis. 2010;25:681-. CrossRef
17. Piattelli A, Fioroni M, Iezzi G, Perrotti V, Stellini E, Piattelli M, et al. CD10 expression in stromal cells of oral cavity squamous cell carcinoma: a clinic and pathologic correlation. Oral Dis. 2006;12:301-. CrossRef
18. Yada K, Kashima K, Daa T, Kitano S, Fujiwara S, Yokoyama S. Expression of CD10 in basal cell carcinoma. Am J Dermatopathol. 2004;26:463-1.- 刊物主题：Surgical Oncology; Oncology; Surgery; Cancer Research;
- 出版者：Springer Japan
- ISSN：1880-4233
文摘
Background Early diagnosis and treatment for breast cancers has greatly improved in recent years, however, subset of this disease with early recurrence have remained to be unpredictable. Several studies has addressed that strong CD10 expression in tumor stroma is associated with poor survival rate of breast cancers, but no correlation between CD10 expression and disease-free survival has been elucidated yet. For these reasons, this study with modified immunohistochemical (IHC) staining evaluated the expression of CD10 in invasive breast carcinomas (IBCs) and analyzed correlations between CD10 expression on tumor cells, stromal cells and myeloid-like cells with clinicopathological parameters and recurrence status. Method IHC staining method was performed on formalin-fixed paraffin-embedded sections of 73 cases of primary IBCs, with record of pathological characteristics of subjects followed up from 1998 to 2007. Results Stromal CD10 expression was observed in 39/73 cases (53.4?%) with strong expression in 41.0?%. Three cases stained positive for myeloid-like cells and five for carcinomatous cells, of which 6 cases had recurrence and/or regional LN status. Stromal CD10 expression was significantly higher in the unfavorable group (69.6?%; 16/23 cases) compared with the favorable group (32.1?%; 9/28 cases) (p?=?0.048). The levels of CD10 expression showed significant difference among clinical outcomes (recurrence or non-recurrence), independent of regional LN status (p?=?0.034), histology type (p?=?0.044), ER status (p?=?0.042), PgR status (p?=?0.039), Her2 status (p?=?0.038) and Ki67 index (p?=?0.036) (partial Pearson correlations). Cox proportional-hazards regression showed that risk factors for disease-free survival were stromal CD10 expression [CD10±, CD10+ versus CD10++; p?=?0.003; HR 2.824 (1.427-.591)]; regional LN status [N0, N1, N2, versus N3; p?=?0.004; HR 2.107 (1.262-.517)] and PgR status [negative versus positive, p?=?0.006, HR 0.172 (0.049-.596)]. Conclusion CD10 expression on stroma with or without other positive tumor cells and/or myeloid-like cells may function as a powerful prognostic factor for IBC disease-free survival rates, predicting of potential recurrence. It can be determined by a simple modified IHC staining method, which is independent of other prognostic morphologic markers and biomarkers in IBC.